GM-CSF in sickle cell anemia patients with elevated Hb F

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Sickle cell anemia (SS) is a genetic blood disorder.
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine involved in immune responses.
• Understanding cytokine levels in SS patients is crucial for disease management.

Purpose of the Study:

• To estimate plasma GM-CSF levels in steady-state SS patients in Kuwait.
• To compare GM-CSF levels between SS patients and healthy/acutely ill controls.
• To investigate potential associations between GM-CSF, Hb F levels, and anemia severity in SS patients.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma GM-CSF.
• Study included 28 steady-state SS patients, 14 healthy Hb AA controls, and 10 acutely ill Hb AA controls.
• SS patients' genotypes (SAI/India, Benin, Bantu haplotypes) and Hb F levels were characterized.

Main Results:

• Detectable plasma GM-CSF was found in 14.3% of steady-state SS patients, 66.7% of SS patients in crisis, 42.9% of healthy controls, and 60% of acutely ill controls.
• No clear association between GM-CSF levels and Hb F or anemia severity was established in steady-state SS patients.
• GM-CSF was detected in SS patients with low Hb F (<2%) and in compound heterozygotes.

Conclusions:

• Plasma GM-CSF can be detected in both sickle cell anemia patients and control subjects.
• The presence of GM-CSF in patients during crisis and in controls suggests involvement of other factors in its production.
• Further research is needed to elucidate the role of GM-CSF and other cytokines in sickle cell pathophysiology.